Analysts Set Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI) Target Price at $5.38

Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI) has been assigned an average rating of “Hold” from the five research firms that are currently covering the stock, Marketbeat.com reports. One research analyst has rated the stock with a sell recommendation, one has given a hold recommendation and three have given a buy recommendation to the company. The average twelve-month price objective among brokerages that have issued ratings on the stock in the last year is $5.3750.

MRVI has been the topic of several recent research reports. Wells Fargo & Company increased their price objective on Maravai LifeSciences from $4.00 to $4.50 and gave the company an “overweight” rating in a research report on Monday, December 15th. Wall Street Zen upgraded Maravai LifeSciences from a “sell” rating to a “hold” rating in a research report on Saturday, February 28th.

Maravai LifeSciences Price Performance

Shares of NASDAQ MRVI opened at $3.11 on Monday. The firm has a market capitalization of $799.49 million, a P/E ratio of -3.46 and a beta of 0.43. The company has a quick ratio of 5.69, a current ratio of 6.60 and a debt-to-equity ratio of 0.85. The stock’s 50-day simple moving average is $3.18 and its two-hundred day simple moving average is $3.33. Maravai LifeSciences has a twelve month low of $1.66 and a twelve month high of $4.11.

Maravai LifeSciences (NASDAQ:MRVI) last announced its earnings results on Wednesday, February 25th. The company reported ($0.04) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.07) by $0.03. The business had revenue of $49.87 million for the quarter, compared to analyst estimates of $49.06 million. Maravai LifeSciences had a negative return on equity of 22.79% and a negative net margin of 70.40%. As a group, equities analysts anticipate that Maravai LifeSciences will post -0.24 EPS for the current fiscal year.

Hedge Funds Weigh In On Maravai LifeSciences

Several institutional investors have recently modified their holdings of the company. T. Rowe Price Investment Management Inc. increased its position in shares of Maravai LifeSciences by 2.9% during the 4th quarter. T. Rowe Price Investment Management Inc. now owns 6,336,680 shares of the company’s stock valued at $20,595,000 after purchasing an additional 178,445 shares during the last quarter. Mackenzie Financial Corp increased its position in shares of Maravai LifeSciences by 1.7% during the 4th quarter. Mackenzie Financial Corp now owns 6,173,656 shares of the company’s stock valued at $20,148,000 after purchasing an additional 104,355 shares during the last quarter. Monaco Asset Management SAM increased its position in shares of Maravai LifeSciences by 315.0% during the 3rd quarter. Monaco Asset Management SAM now owns 3,656,337 shares of the company’s stock valued at $10,494,000 after purchasing an additional 2,775,372 shares during the last quarter. Tejara Capital Ltd increased its position in shares of Maravai LifeSciences by 23.1% during the 4th quarter. Tejara Capital Ltd now owns 3,020,209 shares of the company’s stock valued at $9,816,000 after purchasing an additional 566,768 shares during the last quarter. Finally, Geode Capital Management LLC increased its position in shares of Maravai LifeSciences by 1.2% during the 4th quarter. Geode Capital Management LLC now owns 2,848,105 shares of the company’s stock valued at $9,259,000 after purchasing an additional 34,447 shares during the last quarter. 50.25% of the stock is currently owned by institutional investors.

About Maravai LifeSciences

Maravai LifeSciences Holdings, Inc (NASDAQ: MRVI) is a life sciences company specializing in the development and supply of critical reagents and services for the development and manufacture of biologic therapies. The company’s offerings support a range of applications in genomics, molecular diagnostics, vaccine development and next-generation sequencing. Maravai’s platforms address key challenges in nucleic acid production, protein detection, epigenetic analysis and reagent quality across the biopharmaceutical industry.

Through its product portfolio, which includes proprietary mRNA capping reagents, lipid nanoparticle delivery systems, synthetic oligonucleotides and high-precision assay kits, Maravai enables customers to accelerate research and streamline manufacturing workflows.